ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Perifere neuropathie (PN) geassocieerd met MGUS Richtlijnen en literatuur

Richtlijnen

Er is op dit moment geen richtlijn voor polyneuropathie bij MGUS. 

Literatuur

  1. Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017; 92(5): 838–50
  2. Jaccard A. Monoclonal IgM and neuropathy: not always anti-MAG. Blood 2020; 136:2366-2367
  3. Dalakas MC, Quarles RH, Farrer RG, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996; 40(5): 792–5
  4. Comi G, Roveri L, Swan A, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002; 249(10): 1370–7
  5. Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in antimag polyneuropathy. Neurology. 2008; 71(21): 1742–4
  6. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009; 65(3): 286–93
  7. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatr. 2003; 74(4): 485–9
  8. D'Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017; 176(5): 728–42

 

Ga terug naar de homepage PN geassocieerd met MGUS of lees meer hierover:

Ga terug naar de homepage MGUS.

Ga terug naar de algemene homepage Behandelprotocollen.